{"schema":"sb.node.v1","id":"sb:e/368859d2b7d81df22b193a65","kind":"entity","label":{"text":"novo nordisk","locale":"en"},"identity":{"anchor":"label:en:novo nordisk","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-08T21:52:38.794589+00:00","snapshot":"deploy 42fcb912508e16b96962a1bf0a5ae2df232e259a"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":117,"separatePublishers":45,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-09-03","to":"2026-10-07","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.248: about 75% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto","biotech_pharma","rare_diseases"],"activeDays":34,"assertions":{"regulatory-approval":11,"utterance":7,"launch-release":5,"acquisition":2,"election":1,"ipo-listing":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":10,"byKind":{"observation":10},"withheld":{"state":"withheld","count":2,"reason":"2 receipts withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/4a429cd8e858797b5899bbc6","kind":"observation","label":"The Cryptonomist · 2026-09-29 · Novo Nordisk stock is oversold, but is the 70% collapse from its peak over?","url":"https://en.cryptonomist.ch/2026/09/29/novo-nordisk-stock-is-oversold-but-is-the-70-collapse-from-its-peak-over/"},{"id":"sb:o/36464924e95dacd744f8aeb4","kind":"observation","label":"The Clinical Trial Vanguard · 2026-09-29 · Novo Nordisk Licenses Oral GLP-1/GIP Dual Agonist HRS-1596 From Hengrui for $300M","url":"https://www.clinicaltrialvanguard.com/news/novo-nordisk-licenses-oral-glp-1-gip-dual-agonist-hrs-1596-from-hengrui-for-300m/"},{"id":"sb:o/146284240f9c0cb0e57b996e","kind":"observation","label":"MarketBeat News Feed · 2026-09-29 · Novo Nordisk A/S (NYSE:NVO) Stock Sold Off by Rep. Kevin Hern","url":"https://www.marketbeat.com/instant-alerts/congress-novo-nordisk-as-nyse-nvo-stock-sold-off-by-rep-kevin-hern-2026-09-29/"},{"id":"sb:o/ed5f6328c543fbbc8f8db1d4","kind":"observation","label":"MarketBeat News Feed · 2026-09-25 · Novo Nordisk A/S (NYSE:NVO) Stock Rated \"Hold\" by Sell-Side Brokerages","url":"https://www.marketbeat.com/instant-alerts/consensus-novo-nordisk-as-nyse-nvo-stock-rated-hold-by-sell-side-brokerages-2026-09-25/"},{"id":"sb:o/1e8ac45669835f50e35a4a65","kind":"observation","label":"Fortune · 2026-09-23 · U.S. demand for Novo Nordisk’s weight loss drugs is so huge that the Danish central bank just doubled the nation’s entire growth forecast","url":"https://fortune.com/2026/09/23/novo-nordisk-weight-loss-denmark-economy-growth/"},{"id":"sb:o/496e5e41d1d96048d64cf16a","kind":"observation","label":"MarketWatch · 2026-09-21 · Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s goals for 2030","url":"https://www.marketwatch.com/story/novo-nordisk-stock-tumbles-as-ozempic-maker-sets-out-2030-goals-8a5a8d2d?mod=mw_rss_topstories"},{"id":"sb:o/001dd6433a3a7777ce51eca7","kind":"observation","label":"24/7 Wall St. · 2026-09-16 · Novo Nordisk Expands Obesity Drug to Children, But Market Hesitates on Adoption","url":"https://247wallst.com/investing/2026/09/15/novo-nordisk-expands-obesity-drug-to-children-but-market-hesitates-on-adoption/"},{"id":"sb:o/ea895c66a3cc3fad9f86b9c9","kind":"observation","label":"MarketBeat News Feed · 2026-09-13 · The Manufacturers Life Insurance Company Boosts Stock Holdings in Novo Nordisk A/S $NVO","url":"https://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-boosts-stock-holdings-in-novo-nordisk-as-nvo-2026-09-13/"},{"id":"sb:o/46af8350aeba3853076d9207","kind":"observation","label":"STAT News · 2026-09-11 · STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field","url":"https://www.statnews.com/2026/09/11/novartis-novo-nordisk-cardiovascular-drug-trials-fallout/?utm_campaign=rss"},{"id":"sb:o/9c9ee5453c735d5cb0eb8873","kind":"observation","label":"MarketBeat News Feed · 2026-09-09 · Teamwork Financial Advisors LLC Has $244,000 Stock Position in Novo Nordisk A/S $NVO","url":"https://www.marketbeat.com/instant-alerts/filing-teamwork-financial-advisors-llc-has-244000-stock-position-in-novo-nordisk-as-nvo-2026-09-09/"}],"cursor":null,"order":"newest first; we keep the 10 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with glp-1 (55 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1be62960e6ad4da2c2b9f6cf"},{"kind":"relation","label":"co-mentioned with eli lilly (50 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/73e95c35dd32f4410d3327d7"},{"kind":"relation","label":"co-mentioned with fda (36 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/5e71aa38b14044d1a1be8e4f"},{"kind":"relation","label":"co-mentioned with ai (33 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/ad6c8c963863120b29cd6cf1"},{"kind":"relation","label":"co-mentioned with denmark (31 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4341afabef1810703b4fdf03"},{"kind":"relation","label":"co-mentioned with buy (27 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/90e883d005d447c38efde530"},{"kind":"relation","label":"co-mentioned with china (26 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/03263a72a7f5a83a84d118e7"},{"kind":"relation","label":"co-mentioned with wall street (25 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/559af48198dcb920f1de0e01"},{"kind":"relation","label":"co-mentioned with nyse (19 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c4026b7478307bc05e54d139"},{"kind":"relation","label":"co-mentioned with novartis (17 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1024e626f17300012b9d30a7"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/368859d2b7d81df22b193a65","mcp":"traverse {\"id\":\"sb:e/368859d2b7d81df22b193a65\"}","page":"/entity/novo-nordisk/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/368859d2b7d81df22b193a65\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/368859d2b7d81df22b193a65\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/368859d2b7d81df22b193a65\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/368859d2b7d81df22b193a65\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}